Published in:
09-06-2023 | Lymphoma | Original Research Article
Flow Cytometry of CD5-Positive Hairy Cell Leukemia
Authors:
Diana Cenariu, Ioana Rus, Jon Thor Bergthorsson, Ravnit Grewal, Mihai Cenariu, Victor Greiff, Adrian-Bogdan Tigu, Delia Dima, Cristina Selicean, Bobe Petrushev, Mihnea Zdrenghea, Jonathan Fromm, Carmen-Mariana Aanei, Ciprian Tomuleasa
Published in:
Molecular Diagnosis & Therapy
|
Issue 5/2023
Login to get access
Abstract
Background and Objective
Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder for which diagnosis is typically straightforward, based on bone marrow morphology and flow cytometry (FC) or immunohistochemistry. Nevertheless, variants present atypical expressions of cell surface markers, as is the case of CD5, for which the differential diagnosis can be more difficult. The aim of the current paper was to describe diagnosis of HCL with atypical CD5 expression, with an emphasis on FC.
Methods
The detailed diagnostic methodology for HCL with atypical CD5 expression is presented, including differential diagnosis from other lymphoproliferative diseases with similar pathologic features, by FC analysis of the bone marrow aspirate.
Results
Diagnosis of HCL by means of FC started by gating all events based on side scatter (SSC) versus CD45 and B lymphocytes were selected from the lymphocytes gate as CD45/CD19 positive. The gated cells were positive for CD25, CD11c, CD20, and CD103, while CD10 proved to be dim to negative. Moreover, cells positive for CD3, CD4, and CD8, the three pan-T markers, as well as CD19, showed a bright expression of CD5. The atypical CD5 expression is usually correlated with a negative prognosis and thus chemotherapy with cladribine should be initiated.
Conclusion
HCL is an indolent chronic lymphoproliferative disorder and diagnosis is usually straightforward. However, atypical expression of CD5 renders its differential diagnosis more difficult, but FC is a useful tool that allows an optimal classification of the disease and allows initiation of timely satisfactory therapy.